Table 2.
Male and female patient characteristics
| Males | Females | P value | |
|---|---|---|---|
| n = 1371 | n = 741 | ||
| Age (years) | 76.4 ± 6.7 | 78.1 ± 7.6 | < 0.001 |
| ≥ 65–< 75, n (%) | 680 (49.6) | 264 (35.6) | |
| ≥ 75, (n, %) | 691 (50.4) | 477 (64.4) | |
| BMI (kg/m2) | 23.1 ± 3.9 | 23.2 ± 4.6 | 0.28 |
| < 25, n (%) | 999 (72.9) | 507 (68.4) | |
| ≥ 25, n (%) | 372 (27.1) | 234 (31.6) | |
| HbA1c (%) | 7.1 ± 1.1 | 7.1 ± 1.4 | 0.24 |
| < 7%, n (%) | 714 (52.1) | 409 (55.2) | |
| ≥ 7%, n (%) | 657 (47.9) | 332 (44.8) | |
| eGFR (mL/min/1.73m2) | 54.3 ± 22.2 | 54.7 ± 22.0 | 0.35 |
| Patients with fractures, n (%) | 17 (1.2) | 52 (7.0) | < 0.001 |
| Number of drugs being administered at the time of hospitalization (agents) | 7.7 ± 3.9 | 7.7 ± 3.7 | 0.4 |
| Patients not using hypoglycemic agent, n (%) | 415 (30.3) | 285 (38.4) | < 0.001 |
| Glinide, n (%) | 0 | 0 | – |
| SGLT2 inhibitors, n (%) | 7 (0.5) | 1 (0.1) | 0.25 |
| TZD, n (%) | 109 (8.0) | 39 (5.3) | 0.04 |
| αGI, n (%) | 126 (9.2) | 74 (10.0) | 0.63 |
| BG, n (%) | 268 (19.5) | 139 (18.8) | 0.66 |
| SU, n (%) | 388 (28.3) | 154 (20.8) | 0.001 |
| DPP-4 inhibitors, n (%) | 609 (44.4) | 295 (39.8) | 0.06 |
| GLP-1 receptor agonist, n (%) | 26 (1.9) | 13 (1.8) | 0.84 |
| Insulin, n (%) | 295 (21.4) | 145 (19.6) | 0.38 |
Mean ± S.D., BMI (body mass index), HbA1c (hemoglobin A1c), eGFR (estimated glomerular filtration rate), SGLT2 inhibitors (sodium glucose cotransporter 2 inhibitors), TZD (thiazolidines), αGI (α-glucosidase inhibitors), BG (biguanides), SU (sulfonylureas), DPP-4 inhibitors (dipeptidyl peptidase 4 inhibitors), GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist)